BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 38007241)

  • 1. Therapeutic avenues for γδ T cells in cancer.
    Costa GP; Mensurado S; Silva-Santos B
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
    Saura-Esteller J; de Jong M; King LA; Ensing E; Winograd B; de Gruijl TD; Parren PWHI; van der Vliet HJ
    Front Immunol; 2022; 13():915837. PubMed ID: 35784326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging roles of γδ T cells in cancer immunotherapy.
    Mensurado S; Blanco-Domínguez R; Silva-Santos B
    Nat Rev Clin Oncol; 2023 Mar; 20(3):178-191. PubMed ID: 36624304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gammadelta T lymphocytes in tumor defense.
    Zocchi MR; Poggi A
    Front Biosci; 2004 Sep; 9():2588-604. PubMed ID: 15358583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations.
    Hunter S; Willcox CR; Davey MS; Kasatskaya SA; Jeffery HC; Chudakov DM; Oo YH; Willcox BE
    J Hepatol; 2018 Sep; 69(3):654-665. PubMed ID: 29758330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
    Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
    Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy with γδ T cells: many paths ahead of us.
    Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
    Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.
    Maeurer MJ; Martin D; Walter W; Liu K; Zitvogel L; Halusczcak K; Rabinowich H; Duquesnoy R; Storkus W; Lotze MT
    J Exp Med; 1996 Apr; 183(4):1681-96. PubMed ID: 8666926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human γδ T-Cell Control of Mucosal Immunity and Inflammation.
    McCarthy NE; Eberl M
    Front Immunol; 2018; 9():985. PubMed ID: 29867962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A close look at current γδ T-cell immunotherapy.
    Ma L; Feng Y; Zhou Z
    Front Immunol; 2023; 14():1140623. PubMed ID: 37063836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exhausted intratumoral Vδ2
    Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
    Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep characterization of human γδ T cell subsets defines shared and lineage-specific traits.
    Sanz M; Mann BT; Ryan PL; Bosque A; Pennington DJ; Hackstein H; Soriano-Sarabia N
    Front Immunol; 2023; 14():1148988. PubMed ID: 37063856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies.
    Rao A; Agrawal A; Borthakur G; Battula VL; Maiti A
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. γδ T cell exhaustion: Opportunities for intervention.
    Chen D; Guo Y; Jiang J; Wu P; Zhang T; Wei Q; Huang J; Wu D
    J Leukoc Biol; 2022 Dec; 112(6):1669-1676. PubMed ID: 36000310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
    Nguyen S; Chevalier MF; Benmerzoug S; Cesson V; Schneider AK; Rodrigues-Dias SC; Dartiguenave F; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002184
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.